712 related articles for article (PubMed ID: 28238174)
1. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
2. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Harrington KJ; Andtbacka RH; Collichio F; Downey G; Chen L; Szabo Z; Kaufman HL
Onco Targets Ther; 2016; 9():7081-7093. PubMed ID: 27895500
[TBL] [Abstract][Full Text] [Related]
6. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
7. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Johnson DB; Puzanov I; Kelley MC
Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
[TBL] [Abstract][Full Text] [Related]
10. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
[TBL] [Abstract][Full Text] [Related]
13. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
14. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
16. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
17. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
18. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM; Westbrook B; McKee S; Norwood TG
Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
[TBL] [Abstract][Full Text] [Related]
20. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
